Clinical proteomics: applications for prostate cancer biomarker discovery and detection

被引:45
作者
Petricoin, EF
Ornstein, DK
Liotta, LA
机构
[1] US FDA, Ctr Biol Evaluat & Res, NCI Clin Proteom Program, Off Cell & Gene Therapies, Bethesda, MD 20892 USA
[2] Univ Calif Irvine, Dept Urol, Irvine, CA USA
[3] US FDA, Pathol Lab, Clin Proteom Program, Ctr Canc Res,NCI,NIH, Bethesda, MD 20892 USA
关键词
protein microarray; mass spectrometry; diagnostics; biomarkers; proteomics; pattern recognition;
D O I
10.1016/j.urolonc.2004.04.011
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The science of proteomics comprises much more than simply generating lists of proteins that change in expression as a cause of or consequence of pathophysiology. The goal of proteomics should be to characterize the information flow through the intercellular protein circuitry that communicates with the extracellular microenvironment and then ultimately to the serum/plasma macroenvironment. Serum proteomic pattern diagnostics is a new type of proteomic concept in which patterns of ion signatures generated from high dimensional mass spectrometry data are used as diagnostic classifiers. This recent approach has exciting potential for clinical utility of diagnostic patterns because low molecular weight metabolites, peptides, and protein fragments may have higher accuracy than traditional biomarkers of cancer detection. Intriguingly, we now have discovered that this diagnostic information exists in a bound state, complexed with circulating highly abundant carrier proteins. These diagnostic fragments may one day be harvested by circulating nanoparticles, designed to absorb, enrich, and amplify the repertoire of diagnostic biomarkers generated-even at the critical, initial stages of carcinogenesis. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:322 / 328
页数:7
相关论文
共 33 条
[1]  
Adam BL, 2002, CANCER RES, V62, P3609
[2]   The human plasma proteome - History, character, and diagnostic prospects [J].
Anderson, NL ;
Anderson, NG .
MOLECULAR & CELLULAR PROTEOMICS, 2002, 1 (11) :845-867
[3]   SELECTION OF OPTIMAL PROSTATE-SPECIFIC ANTIGEN CUTOFFS FOR EARLY DETECTION OF PROSTATE-CANCER - RECEIVER OPERATING CHARACTERISTIC CURVES [J].
CATALONA, WJ ;
HUDSON, MA ;
SCARDINO, PT ;
RICHIE, JP ;
AHMANN, FR ;
FLANIGAN, RC ;
DEKERNION, JB ;
RATLIFF, TL ;
KAVOUSSI, LR ;
DALKIN, BL ;
WATERS, WB ;
MACFARLANE, MT ;
SOUTHWICK, PC .
JOURNAL OF UROLOGY, 1994, 152 (06) :2037-2042
[4]   Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease - A prospective multicenter clinical trial [J].
Catalona, WJ ;
Partin, AW ;
Slawin, KM ;
Brawer, MK ;
Flanigan, RC ;
Patel, A ;
Richie, JP ;
deKernion, JB ;
Walsh, PC ;
Scardino, PT ;
Lange, PH ;
Subong, ENP ;
Parson, RE ;
Gasior, GH ;
Loveland, KG ;
Southwick, PC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (19) :1542-1547
[5]   RENAL PROCESSING OF LOW-MOLECULAR WEIGHT PROTEINS [J].
COJOCEL, C ;
MAITA, K ;
BAUMANN, K ;
HOOK, JB .
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY, 1984, 401 (04) :333-339
[6]   High-resolution serum proteomic features for ovarian cancer detection [J].
Conrads, TP ;
Fusaro, VA ;
Ross, S ;
Johann, D ;
Rajapakse, V ;
Hitt, BA ;
Steinberg, SM ;
Kohn, EC ;
Fishman, DA ;
Whiteley, G ;
Barrett, JC ;
Liotta, LA ;
Petricoin, EF ;
Veenstra, TD .
ENDOCRINE-RELATED CANCER, 2004, 11 (02) :163-178
[7]   Cancer diagnosis using proteomic patterns [J].
Conrods, TP ;
Zhou, M ;
Petricoin, EF ;
Liotta, L ;
Veenstra, TD .
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2003, 3 (04) :411-420
[8]   Mass Spectrometry as a diagnostic and a cancer biomarker discovery tool - Opportunities and potential limitations [J].
Diamandis, EP .
MOLECULAR & CELLULAR PROTEOMICS, 2004, 3 (04) :367-378
[9]   Cancer surveillance series: Interpreting trends in prostate cancer - Part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates [J].
Hankey, BF ;
Feuer, EJ ;
Clegg, LX ;
Hayes, RB ;
Legler, JM ;
Prorok, PC ;
Ries, LA ;
Merrill, RM ;
Kaplan, RS .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (12) :1017-1024
[10]  
HINGORANI SR, 2003, CANCER CELL, V4, P6